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Interstitial lung disease (ILD) associated with amyopathic dermatomyositis (ADM) is a rare
and sometimes fatal condition whose clinical features are not well understood. The goal of
this study was to clarify the characteristics of ILD based on its development.
Eighteen patients diagnosed with ILD associated with ADM were assigned to 1 of 2 groups:
(1) a rapidly progressing group, which included patients who developed abnormal lung
findings within 1 month of being diagnosed with ADM (n ¼ 9); or (2) a slowly progressing
group, which including patients who developed lung findings greater than 1 month after
diagnosis of ADM (n ¼ 9).
Serum creatine phosphokinase and C-reactive protein levels were higher in the rapidly
progressing group than in the slowly progressing group. Further, arterial pH was higher and
PaO2/FIO2 was lower in the rapidly progressing group than in the slowly progressing group.
On thoracic high-resolution CT, traction bronchiectasis was present in 4 of the 9 rapidly
progressing patients but not in any patients of the slowly progressing group. All 9 slowly
progressing patients survived with proper treatment, but only 4 of the 9 rapidly progressing
patients survived.
In ADM, appropriate investigations are likely required for the early diagnosis of ILD. Our
data suggest that ILD associated with ADM can be classified into 2 clinical subtypes based
on the time course of pulmonary involvement. Patients with rapid progression in
respiratory symptoms should undergo intensive treatment as soon as possible to promote
favorable outcomes.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Dermatomyositis (DM) is an autoimmune disease that mainly
affects the skin and skeletal muscle. However, a rare form of
DM with no accompanying muscle symptoms was designated
as amyopathic DM (ADM) by Pearson1 or Euwer and
Sontheimerv.2
While treatment-resistant interstitial lung disease (ILD)
may complicate ADM and result in worse prognoses,3–8 the
pathophysiology and clinical course of ADM-associated ILD
remains unclear. Therefore, the goal of this study was to
retrospectively analyze clinical data of patients with ADM-
associated ILD in order to characterize the clinical features
of such condition.
Methods
Patients and diagnostic criteria
This study was performed in accordance with the recom-
mendations of the Helsinki Declaration of 1975,9 and all
investigational protocols were approved by the institutional
review board for human studies of Shinshu University.
Eighteen patients with ADM complicated with ILD (5
males, 13 females), ranging in age from 25 to 71 years, were
treated at the departments of respiratory medicine or
collagen disease in Shinshu University Hospital from 1994 to
2006. Skin biopsies had been performed in all patients, and
the pathological findings were consistent with a diagnosis of
dermatomyositis. All patients met the diagnostic criteria of
ADM as proposed by Euwer and Sontheimer.2 All patients
experienced pulmonary symptoms, including dry cough and
shortness of breath, at some point during the course of their
disease. Chest X-ray showed findings of ILD, according to the
international multidisciplinary consensus classification of
idiopathic interstitial pneumonias proposed by the American
Thoracic Society and the European Respiratory Society,10 in
all patients. We diagnosed them as ADM-associated ILD
based on their clinical course and medical history. We
reviewed the patients’ records with respect to clinical
courses, physical examination, and results of laboratory
studies, including serologic tests, bronchoalveolar lavage
fluid (BALF) examination, pulmonary function tests, and
thoracic computed tomography (CT) scanning. The specific
treatments and outcomes of the patients were also
reviewed.
Clinical assessments
Eighteen patients diagnosed with ILD associated with ADM
were assigned to 1 of 2 groups: (1) a rapidly progressing
group, which included patients who developed abnormal
lung findings within 1 month of being diagnosed with ADM
(n ¼ 9); or (2) a slowly progressing group, which including
patients who developed lung findings greater than 1 month
after diagnosis of ADM (n ¼ 9).
The following clinical parameters were compared be-
tween the groups: age; gender; skin symptoms; biochemical
markers in peripheral blood including anti-Jo-1 antibody,
creatine phosphokinase (CPK) and Krebs von den Lungen 6
(KL-6); arterial blood gas parameters; BALF findings;pulmonary function tests; thoracic high-resolution (HR) CT
findings before treatment; treatments; and clinical course.
Standard laboratory methods were used for the biochemical
laboratory tests and blood gas analysis. Hematoxylin-eosin
staining was used for cellular examination of BALF.
Statistical analysis
Continuous data are expressed as mean7standard error of
the mean (SEM), and categorical data are expressed as
positive ‘‘+’’ or negative ‘‘’’. The unpaired Student’s t-test
was used to analyze continuous variables, and the w2 test
was used to analyze categorical data. A Po0.05 was
regarded as statistically significant.
Results
Clinical course of the rapidly and slowly progressing
groups
As shown in Table 1, the 9 patients in the rapidly progressing
group consisted of 4 males and 5 females (mean age 50.4
years). By contrast, the 9 patients in the slowly progressing
group consisted of 1 male and 8 females (mean age, 44.9
years). The mean age was not significantly different when
comparing the 2 groups.
The mean interval between the onset of respiratory
symptoms, such as dry cough and shortness of breath, and
the diagnosis of ADM was 1672 days (range, 9–25 days) in
the rapidly progressing group and 128743 days (range,
45–210 days) in the slowly progressing group (Table 1).
Skin manifestations
The Gottron’s sign was observed in all patients (Table 1).
Seven of the 9 patients in both groups were positive for
heliotrope rash. Furthermore, skin ulcers were observed in 7
of 9 patients (77.8%) in the rapidly progressing group, while
they were observed in only 3 of 9 patients (33.3%) in the
slowly progressing group.
Laboratory examinations
Anti-Jo-1 antibody titers were negative in all 18 patients
(Table 1). The rapidly progressing group was characterized
by significantly increased levels of CPK and C-reactive
protein (CRP) when compared with the slowly progressing
group (Table 2, CPK: 287.2757.0 vs. 92.1725.0 U/l; P ¼
0.0132, CRP: 2.7570.79 vs. 0.5870.18mg/dl; P ¼ 0.0227).
Results of arterial blood gas analysis at admission are
summarized in Table 2. Since some patients had received
oxygen at their previous medical facilities due to respiratory
failure, the ratio of PaO2 to FIO2 (PaO2/FIO2) was used as a
measure of hypoxemia. The rapidly progressing group had a
significantly higher arterial pH (7.46470.011) and lower
PaO2/FIO2 (252.8725.3 Torr) on admission when compared
with the slowly progressing group (7.41870.011; P ¼
0.0096, 359.4714.2 Torr; P ¼ 0.0020, respectively).
Although there was no significant difference in the BALF
findings when comparing the 2 groups, the percentage of
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Table 1 Overview of the 18 cases of amyopathic dermatomyositis (ADM) complicated with interstitial lung disease.
Patient
number
Age
(years)
Sex Time
interval
(days)
Skin manifestations Anti-Jo-1
antibody
Thoracic CT Treatments Therapeutic
outcome
Gottron’s sign Heliotrope rash Skin ulcer SCS CABB GGO HC TB Corticosteroid CsA Other
therapy
Rapidly progressing group
1 39 F 14 +    + + +  + + +  Improvement
2 25 M 21 +  +  + + +   + + IVIG Improvement
3 65 F 27 + + +  + + +   + + IVIG PE Death
4 46 M 10 + + +  + + +  + + +  Death
5 53 F 15 + + +  + + +   + + IVIG CPA Death
6 71 F 9 + + +  + + +  + + +  Improvement
7 53 F 10 + +   + + +   + +  Improvement
8 46 M 14 + + +  + + +  + +   Death
9 56 M 25 + + +  + + +   + + PE Death
Slowly progressing group
10 42 M 180 + +   + + +   +  CPA Improvement
11 59 F 90 +    + + + +     No change
12 34 F 210 + +   + + +   + +  Improvement
13 46 F 60 + + +  + + +   + +  Improvement
14 42 F 90 + + +  + + +   + +  Improvement
15 38 F 45 +    + + +   +   Improvement
16 53 F 210 + +   + + +   +   Improvement
17 32 F 180 + +   + + +   + +  Improvement
18 58 F 90 + + +  + + +   + +  Improvement
SCS, subpleural curvilinear shadows; CABB, consolidation around bronchovascular bundles; GGO, ground-glass opacities; HC, honey-comb change; TB, traction bronchiectasis; CsA,
cyclosporine A; F, female; M, male; IVIG, intravenous high-dose immunoglobulin; PE, plasma exchange; CPA, cyclophosphamide; +, positive; , negative.
Time interval indicates the interval between the onset of respiratory symptoms (such as dry cough and shortness of breath) and the diagnosis of ADM.
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Table 2 Laboratory findings, cellular fractions of bronchoalveolar lavage fluid and pulmonary functions in the two groups.
Rapidly progressing group Slowly progressing group P value
Peripheral blood
WBC (/ml) 60947668 59427626 0.8714
BUN (mg/dl) 11.071.5 12.671.8 0.5009
Creatinine (mg/dl) 0.5970.04 0.5270.05 0.2514
AST (U/l) 76.0712.8 52.5716.2 0.2670
ALT (U/l) 66.8724.2 29.675.8 0.1790
LDH (U/l) 502.6783.9 312.4750.5 0.0795
CPK (U/ml) 287.2757.0 92.1725.0 0.0132
CRP (mg/dl) 2.7570.79 0.5870.18 0.0227
KL-6 (U/ml) 1243.97335.1 771.9795.7 0.2253
Arterial blood gas
pH 7.46470.011 7.41870.011 0.0096
PaO2/FIO2 (Torr) 252.8725.3 359.4714.2 0.0020
PaCO2 (Torr) 33.971.3 36.471.3 0.1984
HCO3
 (mEq/l) 23.970.7 23.471.3 0.7471
Bronchoalveolar lavage fluid
Macrophages (%) 51.1712.2 47.979.6 0.8378
Neutrophils (%) 27.0712.5 6.673.7 0.1009
Lymphocytes (%) 18.476.9 43.179.5 0.0799
Eosinophils (%) 3.973.2 2.571.8 0.6890
CD4/CD8 1.3070.38 1.2570.38 0.9316
Pulmonary function
VC, % pred 66.379.2 82.278.5 0.1646
FEV1, % pred 88.372.7 78.773.7 0.7545
RV, % pred 144.6721.9 93.079.4 0.0354
DLCO, % pred 50.573.1 59.974.2 0.2013
Values are means7SEM. WBC, white blood cell count; BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine
aminotransferase; LDH, lactate dehydrogenase; CPK, creatine phosphokinase; CRP, C-reactive protein; KL-6, Krebs von den Lungen-6;
% pred, percentage of predicted value; VC, vital capacity; FEV1, forced expiratory volume in 1 s; RV, residual volume; DLCO, diffusion
capacity for carbon monoxide.
Comparisons between the rapidly and slowly progressing groups by unpaired Student’s t-test.
ILD associated with ADM 1409neutrophils was higher and the percentage of lymphocytes
was lower in the rapidly progressing group than in the slowly
progressing group (Table 2).
Pulmonary function testing
The rapidly progressing group was characterized by a
significantly increased percentage of predicted residual
volume (%RV) when compared with the slowly progressing
group (Table 2, 144.6721.9 vs. 93.079.4; P ¼ 0.0354).
Moreover, the percentage of predicted vital capacity (%VC)
was abnormally low in the rapidly progressing group when
compared with normal values (80–120%). Both groups
showed an abnormally low percentage of predicted diffusion
capacity for carbon monoxide (%DLCO) with a normal
percentage of predicted normal forced expiratory volume
in 1 s (%FEV1).
Thoracic HRCT findings
As shown in Table 1, traction bronchiectasis was noted in 4
of 9 patients (44.4%) of the rapidly progressing group, but innone of the patients of the slowly progressing group. Ground
glass opacity, subpleural curvilinear shadows and consolida-
tion around the bronchovascular bundles were seen in all
patients of both groups. Honeycomb change was noted in
only 1 case of the slowly progressing group and in none of
the patients of the rapidly progressing group. A representa-
tive thoracic HRCT image obtained from a patient of the
rapidly progressing group is presented in Fig. 1.Treatment and outcomes
In the rapidly progressing group, corticosteroid was given
with cyclosporine A (CsA) to all patients with the exception
of 1 patient who experienced respiratory failure and died
soon after the onset of pulmonary symptoms (patient 8,
Table 1). Since ILD activity could not be completely
suppressed by corticosteroid and CsA, 4 of the 9 rapidly
progressing patients also received intravenous high-dose
immunoglobulin (IVIG) (patients 2, 3, and 5) and/or plasma
exchange (PE) (patients 3 and 9) and cyclophosphamide
(CPA) treatment (patient 5). However, only 4 of these 9
rapidly progressing patients (44.4%) survived, and the
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Figure 1 High-resolution CT scanning in patient no. 4 of the
rapidly progressing group. Traction bronchiectasis (TB) and
consolidation around bronchovascular bundles (CABB) is present
in the dorsal subpleural area.
G. Ideura et al.1410remainder died due to respiratory failure within 1 month
after the diagnosis of ILD.
In the slowly progressing group, corticosteroid therapy
was used in 8 patients, and CsA was sequentially adminis-
tered to 5 of these 8 patients (Table 1). Patient 10 received
CPA instead of CsA because of a history of an allergic
reaction to CsA. Another patient (patient 11) was followed
without treatment, since her pulmonary symptoms devel-
oped much later and her mild fibrosis was stable on serial
chest X-rays. All patients in the slowly progressing group
survived.
In patients treated with CsA, the daily dose was initiated
at 5mg/kg/day and then carefully adjusted in order to
keep the plasma trough concentration between 100 and
150 ng/ml. When the trough concentration either exceeded
200 ng/ml or was between 150 and 200 ng/ml on 2
successive occasions, the daily dose was reduced by 50mg
at a time. No CsA-related adverse effects were seen in any
of these patients during treatment.Discussion
ADM is a rare form of dermatomyositis that typically
manifests with characteristic cutaneous lesions without
muscle involvement.1,2 In general, lung involvement is
uncommon, and the prognosis is favorable.2,11,12 However,
recent reports have described several cases of fatal ILD
associated with ADM.3–8 In the present study, the mortality
rate of ADM complicated with ILD was 27.8% (5 of the 18
patients), indicating that ILD is an important prognostic
factor for patients with ADM. In the rapidly progressing
group, cutaneous rashes and respiratory symptoms appeared
almost simultaneously (1672 days), and 4 of the 9 patients
died due to respiratory failure within 1 month after thediagnosis of ILD. These data suggest that rapid diagnosis and
initiation of treatment is critical in patients with rapidly
progressing disease and that differentiation of the disease
state based on the temporal course of pulmonary involve-
ment is a clinical relevant characterization.
The progression of systemic stress and inflammation might
result in the significant increases of serum CPK and CRP in
the rapidly progressing group. The elevated BALF neutrophil
level in the rapidly progressing patients may be a reflection
of acute inflammatory destruction of the lung tissues and
have been shown to be associated with treatment resistance
and poor prognosis.13 The abnormal values of %VC, %RV and
%DLCO in pulmonary function examination also suggest
advanced lung involvement in this group. By contrast, the
elevation in BALF lymphocyte counts in the slowly progres-
sing patients may be a reflection of chronic inflammatory
changes that correlate with a relatively stable clinical
course.14 To summarize, these data suggest that elevated
CRP and pulmonary function test abnormalities, such as
decreases in VC and DLCO or an increase in RV, correlate with
the severity of the ILD associated with ADM.
Ground glass opacity, subpleural curvilinear shadow, and
consolidation around bronchovascular bundles are common
findings of ILD associated with dermatomyositis/polymyosi-
tis.15,16 In the present study, the frequency of traction
bronchiectasis was high (44.4%) in the rapidly progressing
group, while no traction bronchiectasis was observed in the
slowly progressing group. Therefore, the presence of
traction bronchiectasis on thoracic CT may be a prognostic
factor in patients with ADM and ILD. This is consistent with a
previous report, in which traction bronchiectasis was more
frequent in non-survivors with acute interstitial pneumonia
than in survivors.17 Likewise, another report on cryptogenic
fibrosing alveolitis demonstrated that severe traction
bronchiectasis was associated with more extensive disease
and physiological impairments than cryptogenic fibrosing
alveolitis with no or mild traction bronchiectasis.18 How-
ever, it is difficult to distinguish rapidly progressing group
from slowly progressing group using HRCT findings other than
traction bronchiectasis. Therefore, a combination of appro-
priate lung investigations is likely required for the early
diagnosis of ILD.
Impairments in the immune response may contribute to
the pathogenesis of ADM. Indeed, the number of CD4-
positive T cells in the peripheral blood is increased in
patients with ADM, and clonal expansion of Th1 cells in the
skin and affected visceral organs, including the lung, may
occur in affected patients.19 In the present study, most
patients with ADM-associated ILD were treated with oral CsA
immunomodulatory therapy along with corticosteroid, since
this treatment strongly and reversibly suppresses T-cell
activity. Another advantage of CsA is that the therapeutic
effects appear within 1 month, whereas the effects of other
immunosuppressive agents usually require at least 2–3
months.20,21 Several studies have reported that CsA has a
good therapeutic effect in patients with ADM-associated ILD.
Four of the 5 patients with ADM-associated ILD resistant to
corticosteroid therapy, including 3 rapidly progressing
patients, showed improvement following the additional
administration of CsA.22 Our previous case report also
clearly demonstrated the efficacy of sequential treatment
of CsA with corticosteroid.23 In the present study, 9 of the 13
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ILD associated with ADM 1411patients (69.2%) showed improvement following the combi-
nation therapy of corticosteroid and CsA. In particular, all
survivors in the rapidly progressing group received corticos-
teroid and CsA and no serious complications ascribable to
CsA were observed during treatment. These data suggest
that CsA is an important therapeutic option for this
condition, and early initiation of treatment including CsA
may result in better outcomes in rapidly progressing
patients.
In summary, the clinical course of ILD associated with ADM
can be distinguished by the time interval to the develop-
ment of pulmonary symptoms. Specifically, patients with a
pulmonary involvement interval shorter than 1 month are
likely to experience rapid destructive damage to both lungs
and have a poor prognosis. Characterization of biochemical
markers, such as CRP in serum, detection of severe
hypoxemia and traction bronchiectasis may also be pre-
dictors of rapid progression and poor prognosis. Patients
with rapid lung involvement should undergo intensive
treatment, such as concurrent corticosteroid and CsA
treatment, as soon as possible in order to promote favorable
outcomes. Further studies with larger patient populations
are required to confirm results from the present study.
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